Skip to content

Clinical trials

Phase 2 Small Cell Lung Carcinoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Small Cell Lung Carcinoma Phase: Phase 2 Clear all

409 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200010
20013
20027
20036
20048
200510
200616
200713
200813
200914
20107
201110
201210
201311
20147
201510
201612
201717
201820
201915
202021
202128
202223
202320
202426
202528
202629

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed148
Unknown status71
Recruiting59
Terminated51
Not yet recruiting34
Active, not recruiting27
Withdrawn15
Enrolling by invitation3
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)25
Shanghai Pulmonary Hospital, Shanghai, China10
Henan Cancer Hospital7
Samsung Medical Center6
Eli Lilly and Company5
GlaxoSmithKline5
M.D. Anderson Cancer Center5
National Cancer Center, Korea5
Peking University Cancer Hospital & Institute5
SCRI Development Innovations, LLC5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Small Cell Lung Carcinoma409
Lung Neoplasms87
Carcinoma, Non-Small-Cell Lung58
Breast Neoplasms15
Uterine Cervical Neoplasms13
Melanoma12
Brain Neoplasms11
Head and Neck Neoplasms11
Squamous Cell Carcinoma of Head and Neck11
Carcinoma, Hepatocellular10

Trials

Showing 76 to 100 of 409. Each trial links to its page on Pharma Observatory.

309 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.